Novartis presents positive Phase III results from JUNIPERA study supporting Cosentyx® as a potential treatment in a JIA population at EULAR 2021
June 02, 2021 01:15 ET
|
Novartis Pharma AG
Phase III JUNIPERA study met its primary endpoint, with Cosentyx® (secukinumab) showing significantly longer time to flare (longer time to worsening of symptoms1) vs. placebo (P<.001) in pediatric...
Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis
June 01, 2021 16:30 ET
|
Novartis Pharma AG
Approval for moderate to severe pediatric patients six years and older is based on pivotal trial data showing Cosentyx demonstrated superior improvements of skin symptoms compared to placebo1 The...
Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program
May 28, 2021 16:30 ET
|
Novartis Pharma AG
Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus...
Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19
May 27, 2021 01:15 ET
|
Novartis Pharma AG
EMPATHY global multi-center Phase 2 - 3 study, recruiting patients with COVID-19 infection, aiming to prevent worsening symptoms and hospitalizationThe study plans to enroll 2100 patients, with 400...
Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer
May 19, 2021 17:00 ET
|
Novartis Pharma AG
Overall survival and radiographic PFS from phase III study of investigational radioligand therapy 177Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be...
Sandoz announces plans to further strengthen its antibiotics manufacturing setup in Europe
May 18, 2021 04:45 ET
|
Novartis Pharma AG
Sandoz to invest €150 million in new antibiotics manufacturing technology in Europe over next three to five years, to be optimally prepared for future needsKundl, Austria further strengthens...
US Supreme Court denies Sandoz petition to review biosimilar Erelzi® (etanercept-szzs) case
May 17, 2021 10:44 ET
|
Novartis Pharma AG
Decision not to review Federal Circuit July 2020 ruling continues to prevent Sandoz launch of more affordable Erelzi treatment option for US patients Sandoz is disappointed US patients affected by...
Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine
May 03, 2021 01:15 ET
|
Novartis Pharma AG
Sandoz to begin enrolling patients with neovascular age-related macular degeneration in MYLIGHT Phase lll confirmatory efficacy and safety study1Neovascular age-related macular degeneration accounts...
Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
May 01, 2021 07:05 ET
|
Novartis Pharma AG
In KESTREL and KITE, Beovu (brolucizumab) 6 mg met the primary endpoints of non-inferiority in change in best corrected visual acuity from baseline versus aflibercept 2 mg at year one in diabetic...
Wichtige Wachstumstreiber und Neueinführungen von Novartis setzen ihre Dynamik im ersten Quartal fort und erhalten das Vertrauen in das Wachstum; Konzernprognose für 2021 bestätigt
April 27, 2021 01:00 ET
|
Novartis Pharma AG
Der Nettoumsatz sank im ersten Quartal um –2% (kWk¹, +1% USD) infolge der COVID-19-bedingten Vorratskäufe im Vorjahr (rund USD 0,4 Milliarden) Die Geschäftseinheit Pharmaceuticals blieb auf...